Lo0se your mind…loose your life Dr. Michael Wald/Dr. Nilay Shah
Transcription
Lo0se your mind…loose your life Dr. Michael Wald/Dr. Nilay Shah
Lo0se your mind…loose your life Dr. Michael Wald/Dr. Nilay Shah Integrative Medicine & Nutrition Clinic 914-242-8844 The information presented herein is meant for educational purposes only and is not meant to replace sound medical or nutritional advice. This material is copyright, 2010 (Dr. Michael Wald) Depression Concentration difficulties Problem with multitasking Memory Moodiness Fatigue Brain-fog-awareness Sleep difficulties Other associated problems: Chemo-neuropathy Surgical/physical Hormonal problems Nutritional imbalances Increased future risk of cancer due to immune suppression Increased risk of infection Neurotoxic effects and other organs The authors examined the long-term cognitive implications of cancer treatment among breast cancer survivors over 65 years old who received treatment during midlife. 30 women survivors were matched with 30 non-cancer, healthy older adults in terms of age, education, and IQ. Cancer survivors scored significantly lower in the cognitive domains of executive functioning, working memory, and divided attention, (frontal-subcortical brain regions). Findings suggest that among breast cancer survivors who remain disease-free for more than a decade, the previous cancer treatment may further augment cognitive dysfunction associated with age-related brain changes. CONCLUSION: Data from this study support the hypothesis that systemic chemotherapy can have a negative impact on cognitive functioning as measured by standardized neuropsychologic tests and self-report of memory changes. “…they (the studies) consistently suggest that between approximately 15% and 25% of chemotherapy-treated breast cancer patients will have evidence of cognitive dysfunction some years after chemotherapy, compared to about 10% of breast cancer survivors who did not receive chemotherapy…” Neuropsychologic deficits and cognitive complaints after systemic cancer chemotherapy Available evidence suggests a fairly diffuse pattern of changes, memory and executive functions could be preferentially affected Preliminary data also suggest that some individuals might be more vulnerable than others Genetic and other risk factors Symptoms associated with cognitive dysfunctiondifficulties with memory, concentration, and language-are frequent among breast cancer survivors after chemotherapy. Models of cognitive dysfunction suggest multiple possible contributors including changes in hormonal milieu, direct effects of chemotherapy, medications given as supportive care, psychiatric changes including depression and anxiety, and mediators of inflammation. Novel neuro-cognitive testing and imaging methods are being evaluated in breast cancer survivors to better understand cognitive side-effects of therapy. “There may be enough data to consider discussing the possibility of cognitive dysfunction as an adverse effect when assessing the risks and benefits of adjuvant chemotherapy” The greatest gap in our knowledge regarding chemotherapy-related cognitive changes Several pathophysiological candidates include Direct neurotoxic effects leading to atrophy of cerebral gray matter (GM) and/or demyelination of white matter (WM) fibers Secondary immunologic responses causing inflammatory reactions, and microvascular injury Altered neurotransmitter levels and metabolites could constitute an additional mechanism related to neurotoxic effects. Directly or indirectly assess many of these mechanisms Very limited application of these tools in studies Morphometric magnetic resonance imaging (MRI), functional MRI (fMRI), diffusion tensor imaging (DTI), and MR spectroscopy (MRS) are noninvasive techniques that could yield important complementary data regarding the nature of neural changes after chemotherapy Electrophysiological studies and targeted molecular imaging with positron emission tomography (PET) could also provide unique information. Encephalopathy (brain swelling) Vasculitis (blood vessel damage/inflammation) White matter damage (plaques) Neurotransmitter abnormaoities Neurotoxicity - Axon, cell body and other CNS damage Electrophysilogic damage (“short circuits”) Malonyldialdehyde – dozens of antioxidants Glutathione reductase – sel, glutathione, etc. Ascorbic acid/dehydroascorbit acid levels – vitamin C Homocysteine/methylmalonic acid: B6, B12, folic acid C-reactive protein – vitamin E, etc. Vitamin D (25-D3 and 1, 25 D3) – Vitamin D analogues Essential fatty acids – omega 3, and omega 6 Phosphotidylcholine, phosphotidylserine – choline, serine, lecithin, etc. Neurotransmitter imbalances – glycine, GABA, tryptophane, etc. B-vitamins – B1, B2, B3, B5, B6, biotin, folic acid, B12, etc. Selenium Magnesium Zinc Autonomic nervous system dysfunction Omega 3 fatty acids L-carnitine B-vitamins Antioxidants Bio-identical Hormones Testosterone Growth hormone Other hormones Detoxification assays Hormonal assays Antioxidant assays Vitamin assays Mineral assays Neuro-degenerative markers CRP Homocysteine Fibrinogen Others TO CONTACT DR. MICHAEL WALD AND DR. NILAY SHAH CALL: